<div id="readability-page-1" class="page"><div>ProImmune Introduces Mastering Immunity 2026 - Shanghai Symposium to Address Key Immunogenicity Challenges<ul> <li> Symposium brings together global leaders in immunogenicity to connect with China’s rapidly evolving pharmaceutical development landscape </li> <li> Speakers include thought leaders in biotherapeutics, complex peptide drug developers, and regulatory authorities </li> <li> In-person event taking place at Oriental Riverside Hotel, Shanghai, 13-14 April 2026 </li> </ul> ProImmune Ltd, a global leader in immunological reagents and services, announced the launch of Mastering Immunity 2026 – Shanghai, an inaugural symposium in China providing practical, real-world guidance to help drug developers manage immunogenicity risk. Taking place at the Oriental Riverside Hotel in Shanghai, the event will convene leading scientists, industry executives, and regulatory professionals from around the world. Immunogenicity, the potential for biologics to trigger unwanted immune responses, remains a decisive factor in determining safety, efficacy, and regulatory and commercial success. When immunogenicity is poorly understood or assessed inadequately, development programs face clinical failure, costly redesigns, and significant delays. In some cases, these risks can lead to the loss of entire programs, representing financial impacts in the hundreds of millions or even billions of dollars, as well as extended timelines required for additional studies or reformulation. Presentations will cover modality-specific insights based on real world examples for emerging therapeutic platforms and perspectives on evolving global regulatory expectations presented by speakers from leading companies and regulators with experience of bringing successful drugs to market, including: <ul> <li> Dr. Zuben Sauna (Director, Center for Biologics Evaluation and Research, FDA) </li> <li> Dr. Sophie Tourdot (Immunogenicity Sciences Lead, Pfizer) </li> <li> Dr. Balaji MR (Vice President and Head – Non Clinical, Dr. Reddy’s Laboratories) </li> <li> Dr. Daniela Verthelyi (Former Chief, Laboratory of Immunology, Office of Biotechnology Products, FDA) </li> <li> Dr. Tim Hickling (Former Head of Immunosafety, Roche, Quasor) </li> <li> Dr. Kanthikiran Varanasi (Global Head of Clinical Affairs, Galencium) </li> <li> Andreas Hollenstein (Senior Principal Scientist, Immunosafety, Roche) </li> <li> Dr. Nitinkumar Dobaria (Associate Director, Injectables Product Development, Lupin) </li> <li> Dr. Anuj Saini (Global Head-Global Clinical Management, Dr Reddy’s Laboratories) </li> <li> Prof. Yoonjoo Choi (Professor, Department of Microbiology and Immunology, Chonnam National University Medical School) </li> </ul> Dr. Juhao Yang, Toxicology Project Leader, China Innovation Center of Roche shared: &#34;This meeting is a pivotal moment, bringing together global leaders to tackle the urgent challenge of immunogenicity risk and drive better patient outcomes. This is a must-attend event for anyone committed to shaping the future of biotherapeutics.” Dr. Nikolai Schwabe, Chief Executive Officer, ProImmune, added: “Licensing activity and clinical trials are at an all-time high in China’s biopharmaceutical industry, but the regulatory landscape is still evolving. By connecting immunogenicity leaders from around the world to share experiences including development and regulatory best practice, ProImmune is playing a critical role in helping developers manage the risk around immunological effects and ultimately accelerate the development of successful therapeutic products.” For event details and registration, including early-bird, visit: https://www.proimmune.com/mastering-immunity-2026-shanghai <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjAxMjE1MTA2NTVyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjAxMjE1MTA2NTVyMQ"/> Media Contact Francesca Wallace Zyme Communications Email: francesca.wallace@zymecommunications.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260121510655/en/</div></div>

ProImmune Ltd 宣布将于 2026 年 4 月 13-14 日在上海东方滨江酒店举办 “掌握免疫力 2026” 研讨会。此次首届活动将聚焦于药物开发中的免疫原性挑战，邀请全球生物治疗领域的领导者和监管机构的专家参与。研讨会旨在提供管理免疫原性风险的实用指导，这些风险可能对药物项目的成功产生重大影响。知名演讲者包括来自 FDA、辉瑞和罗氏的专家。该活动被视为中国生物制药行业从业者的必 attend 会议

ProImmune Introduces Mastering Immunity 2026 - Shanghai Symposium to Address Key Immunogenicity Challenges

- ProImmune 将于 2026 年 4 月 13-14 日在上海举办免疫学研讨会。  
- 该会议聚集了全球免疫学领域的领导者，探讨免疫原性挑战。  
- 会议将提供实践指导，助力药物开发者管理免疫原性风险。

MorningStar

罗氏(ADR)

标普全球医疗股指数 ETF - iShares

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

美国制药 ETF - iShares

Invesco Nasdaq Biotechnology ETF

医疗业 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

辉瑞

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

基因改革 ETF - ARK

纽交所高增长板生物技术指数 ETF - First Trust

Immuneering

医疗业 ETF - Vanguard

ProImmune 推出 “掌握免疫力 2026”——上海研讨会，旨在解决关键的免疫原性挑战